DR. AGARWAL'S EYE HOSP L
Latest filings
- Record date fixed for amalgamation with Dr. Agarwal's Health Care · Compliance
- Merger approved; share exchange record date fixed for November 18 · Strategic Transactions
- Amalgamation with Dr. Agarwal's Health Care effective Nov 1, 2026; 23:2 share swap ratio fixed · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates a chain of 63+ eye care hospitals across India, supported by 250+ doctors, offering ophthalmology services such as consultations, diagnostics, laser treatments and eye surgeries to patients. In FY26, revenue reached ₹470.87 cr (up 18.6% YoY from ₹397.15 cr) with net profit of ₹70.10 cr and EBITDA margin of 32.1%. Other operating expenses form the largest cost line at 39.7% of revenue, followed by employee costs at 19.5%, consistent with a labour-intensive hospital model. Capex runs at 20.9% of revenue, supporting the addition of new centres and equipment. The Board declared total dividends of ₹7 per share for FY26 (interim ₹3 plus final ₹4) and raised ₹70 cr via a preferential issue to its holding company. A scheme to merge the listed company into its parent Dr. Agarwal's Health Care Limited, which runs 288 Indian facilities across 14 states and 5 UTs plus 19 facilities in Africa and already owns 72.67%, was approved by shareholders and creditors in July 2026, pending NCLT sanction.
Scorecard
Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from DR. AGARWAL'S EYE HOSP L's filed financials and exchange disclosures
What does DR. AGARWAL'S EYE HOSP L do?
DR. AGARWAL'S EYE HOSP L is a Healthcare Services company listed on NSE and BSE, trading under the symbol DRAGARWQ.
Is DR. AGARWAL'S EYE HOSP L profitable?
Yes. Over the trailing twelve months DR. AGARWAL'S EYE HOSP L reported a net profit of ₹70 Cr on revenue of ₹471 Cr.
Does DR. AGARWAL'S EYE HOSP L pay a dividend?
Yes. The dividend yield is 0.13% at the current price. It paid out 4% of its profit as dividend in FY26.
Is DR. AGARWAL'S EYE HOSP L debt-free?
No. It reported borrowings of ₹82 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹75 Cr after cash. Debt stands at 0.24× equity. That is lower than 52% of its 24 Hospital peers.
Is DR. AGARWAL'S EYE HOSP L expensive compared with its peers?
On trailing P/E, DR. AGARWAL'S EYE HOSP L ranks 12 of 30 in Hospital — cheaper than 62% of them, against an industry median of 42.0×. This is a position, not a valuation judgement.
How much does the DR. AGARWAL'S EYE HOSP L share price move in a day?
On a typical session DR. AGARWAL'S EYE HOSP L moves 1.01% — that is the median absolute close-to-close move across its last 130 trading days. MarketPing measures each filing's price reaction against it.
Where can I track DR. AGARWAL'S EYE HOSP L's announcements?
Every NSE and BSE filing by DR. AGARWAL'S EYE HOSP L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.